{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:36:08Z","timestamp":1787240168562,"version":"build-2736575974"},"reference-count":129,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014935","name":"BioCryst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jaip.2021.03.012","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T05:20:40Z","timestamp":1623043240000},"page":"2170-2184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["What\u2019s New in the Treatment of Urticaria and Angioedema"],"prefix":"10.1016","volume":"9","author":[{"given":"David A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emek","family":"Kocat\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Ayg\u00f6ren-P\u00fcrs\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.03.012_bib1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/cea.13309","article-title":"Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study","volume":"49","author":"Maurer","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib3","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13023-018-0815-5","article-title":"Epidemiology of bradykinin-mediated angioedema: a systematic investigation of epidemiological studies","volume":"13","author":"Aygoren-Pursun","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2021.03.012_bib5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2500\/aap.2018.39.4123","article-title":"Hereditary angioedema from the patient\u2019s perspective: a follow-up patient survey","volume":"39","author":"Banerji","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2021.03.012_bib6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2500\/aap.2010.31.3394","article-title":"The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression","volume":"31","author":"Lumry","year":"2010","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2021.03.012_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1750-1172-9-99","article-title":"Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe","volume":"9","author":"Aygoren-Pursun","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2021.03.012_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2500\/aap.2013.34.3685","article-title":"The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe","volume":"35","author":"Caballero","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2021.03.012_bib9","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"175","author":"Guillen-Aguinaga","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib11","doi-asserted-by":"crossref","DOI":"10.18176\/jiaci.0649","article-title":"Up-dosing antihistamines in chronic spontaneous urticaria: efficacy and safety. A systematic review of the literature","volume":"31","author":"Iriarte Sot\u00e9s","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib12","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/cea.13500","article-title":"Cardiac safety of second-generation H(1)-antihistamines when updosed in chronic spontaneous urticaria","volume":"49","author":"Cataldi","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib13","first-page":"5615109","article-title":"Cutting edge: biomarkers for chronic spontaneous urticaria","volume":"2018","author":"Folci","year":"2018","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.jaip.2021.03.012_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/all.14547","article-title":"Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","article-title":"Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of \u201creal-world\u201d evidence","volume":"155","author":"Tharp","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib16","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaip.2018.01.027","article-title":"Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria","volume":"6","author":"Turk","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","article-title":"Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence","volume":"59","author":"Metz","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaip.2017.05.018","article-title":"The expanding field of biologics in the management of chronic urticaria","volume":"5","author":"Joshi","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaip.2019.07.021","article-title":"How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers","volume":"8","author":"T\u00fcrk","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13601-016-0139-2","article-title":"Looking forward to new targeted treatments for chronic spontaneous urticaria","volume":"7","author":"Kocaturk","year":"2017","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib22","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we do not know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clim.2017.11.004","article-title":"Treatment of chronic spontaneous urticaria: immunomodulatory approaches","volume":"190","author":"de Montjoye","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","article-title":"Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review","volume":"6","author":"Kulthanan","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib25","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jaip.2020.02.012","article-title":"Cyclosporine and omalizumab together: a new option for chronic refractory urticaria","volume":"8","author":"S\u00e1nchez","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4168\/aair.2019.11.5.736","article-title":"Factors predicting the response to cyclosporin treatment in patients with chronic spontaneous urticaria: a systematic review","volume":"11","author":"Kulthanan","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2021.03.012_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cea.12494","article-title":"BSACI guideline for the management of chronic urticaria and angioedema","volume":"45","author":"Powell","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4168\/aair.2016.8.5.396","article-title":"Guideline of chronic urticaria beyond","volume":"8","author":"Fine","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2021.03.012_bib29","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMra033121","article-title":"Advances in H1-antihistamines","volume":"351","author":"Simons","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1185\/03007995.2012.672405","article-title":"Safety considerations in the management of allergic diseases: focus on antihistamines","volume":"28","author":"Yanai","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2021.03.012_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/164_2016_85","article-title":"Allergy, histamine and antihistamines","volume":"241","author":"Church","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jaip.2021.03.012_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1398-9995.2009.02325.x","article-title":"Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper","volume":"65","author":"Church","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib33","first-page":"419","article-title":"Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists","volume":"74","author":"Witek","year":"1995","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1517\/14740338.2015.989831","article-title":"Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine","volume":"14","author":"Hiraoka","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2021.03.012_bib35","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bcp.12421","article-title":"Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers","volume":"78","author":"Farr\u00e9","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2021.03.012_bib36","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1164\/ajrccm.164.supplement_1.2103025","article-title":"Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders","volume":"164","author":"Schulman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib39","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000507218","article-title":"Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020","volume":"181","author":"Maurer","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cea.12870","article-title":"Potential blood biomarkers in chronic spontaneous urticaria","volume":"47","author":"Kolkhir","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s40521-017-0145-1","article-title":"Role of biologics and future perspectives in the treatment of urticaria","volume":"4","author":"Kocaturk","year":"2017","journal-title":"Curr Treatment Options Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib43","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2017.01.042","article-title":"Omalizumab is effective in symptomatic dermographism\u2014results of a randomized placebo-controlled trial","volume":"140","author":"Maurer","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib44","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jaci.2017.01.043","article-title":"Omalizumab is effective in cold urticaria\u2014results of a randomized placebo-controlled trial","volume":"140","author":"Metz","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib45","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jaip.2018.12.025","article-title":"Efficacy and safety of omalizumab (Xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial","volume":"7","author":"Gastaminza","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib46","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaad.2015.11.021","article-title":"Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study","volume":"74","author":"Aubin","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/bjd.19425","article-title":"Omalizumab for the treatment of chronic inducible urticaria in 80 patients","volume":"184","author":"Exposito-Serrano","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jaip.2021.03.012_bib49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2133.2000.03664.x","article-title":"Randomized double-blind study of cyclosporin in chronic \u2018idiopathic\u2019 urticaria","volume":"143","author":"Grattan","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1081-1206(10)60462-0","article-title":"Therapeutic alternatives for chronic urticaria: an evidence-based review, part 1","volume":"100","author":"Morgan","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1081-1206(10)60047-6","article-title":"Therapeutic alternatives for chronic urticaria: an evidence-based review, part 2","volume":"100","author":"Morgan","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaip.2013.06.003","article-title":"Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use","volume":"1","author":"Khan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib53","first-page":"e12993","article-title":"Doxepin in difficult-to-treat chronic urticaria: a retrospective, cross-sectional study from Turkey","volume":"32","author":"\u00d6zkaya","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2021.03.012_bib54","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0091-6749(86)90232-0","article-title":"Efficacy of doxepin in the treatment of chronic idiopathic urticaria","volume":"78","author":"Goldsobel","year":"1986","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib55","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.anai.2014.01.010","article-title":"Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: a randomized study","volume":"112","author":"Rorie","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib56","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/09546634.2011.593485","article-title":"Autologous whole blood and autologous serum injections are equally effective as placebo injections in reducing disease activity in patients with chronic spontaneous urticaria: a placebo controlled, randomized, single-blind study","volume":"23","author":"Kocat\u00fcrk","year":"2012","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jaip.2021.03.012_bib57","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/09546634.2019.1572863","article-title":"Efficacy of autologous whole blood or serum therapy for chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"30","author":"Chang","year":"2019","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jaip.2021.03.012_bib58","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/jdv.15640","article-title":"Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria","volume":"33","author":"Yu","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2021.03.012_bib59","author":"\u00d6zg\u00fcl \u00d6zdemir"},{"key":"10.1016\/j.jaip.2021.03.012_bib60","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaip.2020.11.043","article-title":"Biologics for the use in chronic spontaneous urticaria: when and which?","volume":"9","author":"Maurer","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/09546634.2017.1329505","article-title":"Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence","volume":"29","author":"Holm","year":"2018","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.jaip.2021.03.012_bib62","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2340\/00015555-0434","article-title":"Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial","volume":"88","author":"Engin","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2021.03.012_bib63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjd.14778","article-title":"Phototherapy using narrowband ultraviolet B and psoralen plus ultraviolet A is beneficial in steroid-dependent antihistamine-refractory chronic urticaria: a randomized, prospective observer-blinded comparative study","volume":"176","author":"Bishnoi","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib64","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jaip.2014.06.004","article-title":"Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria","volume":"2","author":"Morgan","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib65","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamadermatol.2018.3715","article-title":"Use of dapsone in the treatment of chronic idiopathic and autoimmune urticaria","volume":"155","author":"Liang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib66","doi-asserted-by":"crossref","first-page":"100033","DOI":"10.1016\/j.waojou.2019.100033","article-title":"Comparing azathioprine with cyclosporine in the treatment of antihistamine refractory chronic spontaneous urticaria: a randomized prospective active-controlled non-inferiority study","volume":"12","author":"Pathania","year":"2019","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2021.03.012_bib67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2009.09538.x","article-title":"Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria","volume":"162","author":"Perez","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib68","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaad.2019.07.097","article-title":"Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: a randomized, controlled trial","volume":"82","author":"Leducq","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib69","doi-asserted-by":"crossref","first-page":"e14077","DOI":"10.1111\/dth.14077","article-title":"Efficacy of methotrexate as add on therapy to H1 antihistamine in difficult to treat chronic urticaria: a systematic review and meta-analysis of randomized clinical trials","volume":"33","author":"Patil","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2021.03.012_bib70","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jaip.2020.10.056","article-title":"\u2018Omalizumab plus\u2019: combining omalizumab with immunosuppression for treatment of refractory chronic urticaria: a multi-center UK series","volume":"9","author":"Rutkowski","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib71","doi-asserted-by":"crossref","first-page":"100448","DOI":"10.1016\/j.waojou.2020.100448","article-title":"Combination therapy with omalizumab and an immune-suppressive agent for resistant chronic spontaneous urticaria\u2014a real-life experience","volume":"13","author":"Maoz-Segal","year":"2020","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2021.03.012_bib72","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1444-0903.2004.00532.x","article-title":"Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation","volume":"34","author":"Reeves","year":"2004","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaip.2021.03.012_bib73","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.anai.2013.09.028","article-title":"Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria","volume":"112","author":"Orden","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib74","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/dth.12266","article-title":"Delayed pressure urticaria: response to treatment with sulfasalazine in a case series of seventeen patients","volume":"28","author":"Swerlick","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2021.03.012_bib75","first-page":"1423","article-title":"Treatment of chronic urticaria with colchicine","volume":"10","author":"Pho","year":"2011","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib76","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.jaip.2018.12.023","article-title":"Effectiveness and safety of oral tacrolimus in refractory chronic urticaria","volume":"7","author":"Dorman","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib77","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jaad.2011.06.004","article-title":"The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients","volume":"66","author":"Zimmerman","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2021.03.012_bib78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaip.2016.08.010","article-title":"The comparative safety of multiple alternative agents in refractory chronic urticaria patients","volume":"5","author":"Seth","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib79","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/all.12437","article-title":"Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology","volume":"69","author":"Muraro","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib80","author":"de Silva"},{"key":"10.1016\/j.jaip.2021.03.012_bib81","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14656566.2017.1282461","article-title":"Current and future therapies for the treatment of histamine-induced angioedema","volume":"18","author":"James","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaip.2021.03.012_bib82","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s40629-014-0009-1","volume":"23","author":"Ring","year":"2014","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2021.03.012_bib83","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13601-017-0141-3","article-title":"Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria","volume":"7","author":"van den Elzen","year":"2017","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib84","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jaip.2018.04.026","article-title":"Montelukast reduces symptom severity and frequency in patients with angioedema-predominant chronic spontaneous urticaria","volume":"6","author":"Akenroye","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib85","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/all.12870","article-title":"Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial","volume":"71","author":"Staubach","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib86","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/all.13339","article-title":"Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data","volume":"73","author":"Staubach","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib87","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib88","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib89","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib90","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaci.2017.10.018","article-title":"The XTEND-CIU study: long-term use of omalizumab in chronic idiopathic urticaria","volume":"141","author":"Maurer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib91","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib93","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.iac.2006.08.001","article-title":"Angiotensin-converting enzyme inhibitor-associated angioedema","volume":"26","author":"Byrd","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.03.012_bib94","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/pds.4260","article-title":"Antihypertensive drug associated angioedema: effect modification by race\/ethnicity","volume":"26","author":"Reichman","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaip.2021.03.012_bib95","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1573399813666170214113856","article-title":"Dipeptidyl peptidase-4 inhibitor induced angioedema\u2014an overlooked adverse drug reaction?","volume":"14","author":"Scott","year":"2018","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.jaip.2021.03.012_bib96","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.jaip.2021.03.012_bib97","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.07371009","article-title":"Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients","volume":"5","author":"Duerr","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jaip.2021.03.012_bib98","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1161\/STROKEAHA.116.013334","article-title":"Orolingual angioedema during or after thrombolysis for cerebral ischemia","volume":"47","author":"Myslimi","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jaip.2021.03.012_bib99","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors","volume":"110","author":"Makani","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaip.2021.03.012_bib100","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/joim.12867","article-title":"Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors\u2014a nationwide registry-based cohort study","volume":"285","author":"Rasmussen","year":"2019","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib101","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.annemergmed.2010.03.032","article-title":"Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series","volume":"56","author":"Bas","year":"2010","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib102","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11739-015-1205-9","article-title":"Treatment of ACEI-related angioedema with icatibant: a case series","volume":"10","author":"Bova","year":"2015","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib103","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJMoa1312524","article-title":"A\u00a0randomized trial of icatibant in ACE-inhibitor-induced angioedema","volume":"372","author":"Ba\u015f","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib104","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaci.2016.09.051","article-title":"Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema","volume":"140","author":"Straka","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib105","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaip.2017.03.003","article-title":"Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway angioedema","volume":"5","author":"Sinert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib106","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.annemergmed.2014.07.014","article-title":"Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial","volume":"65","author":"Lewis","year":"2015","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib107","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.anai.2014.12.007","article-title":"Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department","volume":"114","author":"Bernstein","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib108","doi-asserted-by":"crossref","first-page":"E198","DOI":"10.1002\/lary.25113","article-title":"Effect of C1-esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema","volume":"125","author":"Greve","year":"2015","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2021.03.012_bib109","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/all.13384","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2017 revision and update","volume":"73","author":"Maurer","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/imt.14.33","article-title":"Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema","volume":"6","author":"Bork","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaip.2021.03.012_bib111","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib112","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0805538","article-title":"Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema","volume":"363","author":"Zuraw","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib113","doi-asserted-by":"crossref","first-page":"938.e1","DOI":"10.1016\/j.amjmed.2012.02.020","article-title":"Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema","volume":"125","author":"Zuraw","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib114","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/pai.13060","article-title":"A\u00a0randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema","volume":"30","author":"Aygoren-Pursun","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib115","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/all.12658","article-title":"Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate","volume":"70","author":"Zuraw","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib116","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib117","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jaip.2017.12.039","article-title":"Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema","volume":"6","author":"Lumry","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib118","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-019-0362-1","article-title":"Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study","volume":"28","author":"Li","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib119","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jaip.2019.01.054","article-title":"Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks","volume":"7","author":"Craig","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.012_bib120","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1089\/ped.2020.1143","article-title":"Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema","volume":"33","author":"Levy","year":"2020","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"10.1016\/j.jaip.2021.03.012_bib121","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13223-020-0409-3","article-title":"Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial","volume":"16","author":"Levy","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.012_bib122","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/cts.12806","article-title":"Pharmacokinetics, pharmacodynamics, and exposure-response of lanadelumab for hereditary angioedema","volume":"13","author":"Wang","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaip.2021.03.012_bib123","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1605767","article-title":"Inhibiting plasma kallikrein for hereditary angioedema prophylaxis","volume":"376","author":"Banerji","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib124","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2021.03.012_bib125","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14680","article-title":"Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study","volume":"76","author":"Lumry","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib126","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1111\/all.14416","article-title":"Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks","volume":"75","author":"Riedl","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.012_bib127","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1716995","article-title":"Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema","volume":"379","author":"Aygoren-Pursun","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.012_bib128","author":"Zuraw"},{"key":"10.1016\/j.jaip.2021.03.012_bib129","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(17)31963-3","article-title":"Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial","volume":"390","author":"Riedl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.03.012_bib135","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1915035","article-title":"Antisense inhibition of prekallikrein to control hereditary angioedema","volume":"383","author":"Cohn","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821003160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821003160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:29:03Z","timestamp":1761974943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821003160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2213219821003160"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.03.012","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What\u2019s New in the Treatment of Urticaria and Angioedema","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}